Literature DB >> 11133185

Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA.

J P Wood1, L DeSantis, H M Chao, N N Osborne.   

Abstract

It has previously been reported that the beta(1)-adrenoceptor antagonist, betaxolol, can protect retinal neurones from ischaemia when applied topically. It has further been shown that betaxolol can reduce influx of both sodium or calcium into neurones through interaction at neurotoxin site 2 of the sodium channel and the L-type calcium channel, respectively. The present study sought to further investigate the neuroprotective mode of action of betaxolol in the rat retina. Rats were treated topically with L-betaxolol for 10, 5 and 1 min before ischaemia, induced by raising the intraocular pressure above systolic blood pressure for 45 min. This was followed by reperfusion of 3 or 5 days where L-betaxolol was applied topically twice daily. Ischaemia plus reperfusion caused both a loss of immunoreactivity for choline acetyl transferase (ChAT) and a marked reduction of the b-wave of the electroretinogram (ERG). Treatment, as described, with topical L-betaxolol, completely blunted the effects upon ChAT immunoreactivity and caused a significant reversal of the ERG changes. Furthermore, other rats treated topically with commercially available racemic betaxolol (Betoptic Solution, 0.5%) for 6 hr had raised levels of mRNA for brain derived neurotrophic factor (BDNF) but not for basic fibroblast growth factor (bFGF) in their retinas. The combined data provide further evidence that betaxolol can blunt the effects of ischaemia to the rat retina when applied topically just before the insult. Furthermore, the finding that retinal levels of BDNF mRNA are raised following topical betaxolol treatment shows that not only can this drug reach the retina but that it can also induce changes in expression of factors which are known, themselves, to provide neuroprotection to retinal neurones. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133185     DOI: 10.1006/exer.2000.0929

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  13 in total

Review 1.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

3.  Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model.

Authors:  M Seki; T Tanaka; H Matsuda; T Togano; K Hashimoto; J Ueda; T Fukuchi; H Abe
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

Review 4.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Treatment of nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Surv Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 6.048

Review 6.  Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina.

Authors:  A J Weber; C D Harman; S Viswanathan
Journal:  J Physiol       Date:  2008-06-19       Impact factor: 5.182

7.  Metipranolol attenuates lipid peroxidation in rat brain: a comparative study with other antiglaucoma drugs.

Authors:  José Melena; Neville N Osborne
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-07-29       Impact factor: 3.117

8.  In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells.

Authors:  Pascale Hamard; Catherine Blondin; Caroline Debbasch; Jean-Michel Warnet; Christophe Baudouin; Françoise Brignole
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-07       Impact factor: 3.117

Review 9.  Advanced glaucoma: management pearls.

Authors:  Girum W Gessesse; Karim F Damji
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Apr-Jun

Review 10.  Glaucoma -state of the art and perspectives on treatment.

Authors:  Anna Wójcik-Gryciuk; Małgorzata Skup; Wioletta J Waleszczyk
Journal:  Restor Neurol Neurosci       Date:  2015       Impact factor: 2.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.